Medical Screening News
-
Infection Control Resources to Identify Klebsiella and Other Pathogens in Healthcare Settings throughout Puerto Rico
The Centers for Disease Control and Prevention (CDC) describes Klebsiella as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). These include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. The agency warns Klebsiella bacteria have increasingly developed antimicrobial resistance, most recently to the ...
-
Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...
-
Klebsiella in Healthcare Settings Discussed in New Online Video
The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses Klebsiella, a type of gram-negative bacteria that can cause various healthcare-associated infections (HAIs). “HAIs due to Klebsiella can include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis,” said ...
-
Empowering Patient Care: Global Medical Kiosks Market Poised for Remarkable 14.8% CAGR, According to BCC Research
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a thorough analysis of its current landscape and future ...
By BCC Research
-
(Viral) Vaccine Manufacturing
It is well accepted that vaccination is one of the most effective ways to prevent diseases. A vaccine helps the body’s immune system to recognize and fight pathogens like bacteria or viruses, which then keeps humans safe from the diseases they cause. Vaccines protect against a range of diseases, including measles, polio, diphtheria, tetanus, meningitis, influenza and cancer. ...
By Nuvonis
-
LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures
LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. The clinical use of this product is expected ...
By RevBio Inc.
-
Successful Scale up of the Production Process for Abera Bioscience’s First Vaccine
Abera Bioscience, which develops vaccines and immunotherapies based on its own vaccine platforms, has successfully scaled up the production process for the company’s first vaccine, a nasal vaccine against pneumococcus, that causes e.g. pneumonia and meningitis. The project was carried out at Testa Center – a test bed for biotechnological production processes that are supported by ...
-
OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate ...
By OpGen, Inc.
-
Vaccine trial to investigate a booster for teenagers to protect against COVID-19
Researchers running the University of Oxford-led Com-COV programme have launched a further national study assessing different options for a (third dose) booster vaccination for young people aged 12 to 15. Backed through funding from the Vaccines Taskforce and National Institute for Health Research (NIHR), the Com-COV 3 trial will seek to recruit 270 volunteers across the UK. In Wales, up to 40 ...
By MediWales
-
CDx Diagnostics’ WATS3D Participates in Highmark, Inc. Health Plans in Delaware, Pennsylvania, and West Virginia
WATS3D, an AI powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barrett’s esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021. CDx Diagnostics is pleased to share, that effective immediately, ...
-
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for ...
-
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
-
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to ...
-
January is Cervical Cancer Awareness Month
According to the National Cervical Cancer Coalition, more than 14,000 women in the United States are diagnosed with invasive cervical cancer each year, but the disease is preventable with vaccination and appropriate screening. At Cyalume, making strides to enhance medical screenings for women is our main priority. It drives our motivation and was the impetus for the SpecuLume EZ, our single use, ...
-
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today ...
-
The Newly Developed Metabolomics Platform Brings New Insights into Enteroaggregative E. coli
With years of experience in metabolomics services, Creative Proteomics has developed a microbial metabolome analysis platform dedicated to providing high-quality, personalized microbial metabolomics services and reliable data support to clients worldwide. Microorganisms have existed on Earth for at least 3.8 billion years and are found in almost all corners of the biosphere. The diversity of ...
-
CDx Diagnostics’ WATS3D Receives “Medically Necessary” Designation from Highmark Health Plans
WATS3D, a diagnostic platform developed by CDx Diagnostics to empower physicians to detect Barrett’s esophagus (BE) and esophageal dysplasia, has been designated as medically necessary by Highmark Blue Cross Blue Shield plans in Delaware, Pennsylvania, and West Virginia. Clinically proven to significantly increase the detection rate of BE, pre-cancer, and cancerous cells in the esophagus ...
-
HD Medical’s HD Steth Screens Over 50,000 Children for Congenital Heart Defects
In recognition of World Congenital Heart Defects (CHD) Awareness week, HD Medical Inc. today announces it has screened over 50,000 children for CHDs using HD Steth™. These screenings have been conducted at multiple locations in India, helping to save over 35 lives to date. HD Medical plans to expand the screenings to over 500,000 children worldwide. The children diagnosed with CHD were ...
-
First Patients Enrolled in Balt STEM Trial
Balt announced today that the first patients have been enrolled in the clinical trial; The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic subdural hematoma [NCT04410146]. This marks the first patients enrolled in a prospective, randomized, international trial of a liquid embolic agent for the treatment of chronic subdural hematoma (cSDH), a ...
-
EPA Announces Proposed Updates to List of Pests of Significant Health Importance
On November 4, 2020, the U.S. Environmental Protection Agency (EPA) published a notice in the Federal Register announcing the release of an updated list of pests of significant health importance for public review and comment. 85 Fed. Reg. 70146. EPA, in coordination with the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Agriculture (USDA), identifies pests of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you